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ARCHIVAL REPORTL-DOPA Treatment Selectively Restores Spine Density
in Dopamine Receptor D2–Expressing Projection
Neurons in Dyskinetic Mice
Luz M. Suárez, Oscar Solís, Jose M. Caramés, Irene R. Taravini, Jose M. Solís,
Mario G. Murer, and Rosario MoratallaBackground: L-3,4-dihydroxyphenylalanine (L-DOPA)–induced dyskinesia is an incapacitating complication of L-DOPA therapy that
affects most patients with Parkinson’s disease. Previous work indicating that molecular sensitization to dopamine receptor D1 (D1R)
stimulation is involved in dyskinesias prompted us to perform electrophysiological recordings of striatal projection “medium spiny
neurons” (MSN). Moreover, because enhanced D1R signaling in drug abuse induces changes in spine density in striatum, we investigated
whether the dyskinesia is related to morphological changes in MSNs.
Methods: Wild-type and bacterial artiﬁcial chromosome transgenic mice (D1R-tomato and D2R–green ﬂuorescent protein) mice were
lesioned with 6-hydroxydopamine and subsequently treated with L-DOPA to induce dyskinesia. Functional, molecular, and structural
changes were assessed in corticostriatal slices. Individual MSNs injected with Lucifer-Yellow were detected by immunohistochemistry for
three-dimensional reconstructions with Neurolucida software. Intracellular current-clamp recordings with high-resistance micropipettes
were used to characterize electrophysiological parameters.
Results: Both D1R-MSNs and D2R-MSNs showed diminished spine density in totally denervated striatal regions in parkinsonian mice.
Chronic L-DOPA treatment, which induced dyskinesia and aberrant FosB expression, restored spine density in D2R-MSNs but not in D1R-
MSNs. In basal conditions, MSNs are more excitable in parkinsonian than in sham mice, and excitability decreases toward normal values after
L-DOPA treatment. Despite this normalization of basal excitability, in dyskinetic mice, the selective D1R agonist SKF38393 increased the
number of evoked action potentials in MSNs, compared with sham animals.
Conclusions: Chronic L-DOPA induces abnormal spine re-growth exclusively in D2R-MSNs and robust supersensitization to D1R-
activated excitability in denervated striatal MSNs. These changes might constitute the anatomical and electrophysiological substrates of
dyskinesia.Key Words: Behavioral sensitization, dyskinesia, L-DOPA, medium
spiny neuron, Parkinson’s disease, striatum, three-dimensional
neuronal reconstruction
An almost complete loss of dopaminergic ﬁbers in themotor region of the striatum results in the profoundakinesia that characterizes advanced Parkinson’s disease
(PD) (1). At this stage most patients need chronic L-3,4-dihydro-
xyphenylalanine (L-DOPA) therapy, and many will develop
L-DOPA-induced dyskinesia (2). Knowledge gained in recent years
about the molecular mechanisms underlying dyskinesias has not
yet resulted in improved therapies.
This might be due in part to the occurrence of structural
changes in the striatal microcircuit. Postmortem studies have
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Subsequent studies revealed a decrease in spine density in MSNs
of L-DOPA-treated patients (4,5). In parallel, Ingham et al. (6,7)
showed a reduction of spine density in MSNs in rats with
unilateral nigrostriatal lesion, a ﬁnding conﬁrmed in additional
animal models of PD (8–10). Although pruning of dendritic spines
in striatal neurons at late stages of PD and in animal models of PD
has been repeatedly reported, it is not clear whether it is modiﬁed
by L-DOPA therapy.
Importantly, sensitization of dopamine receptor D1 (D1R)
signaling cascade in MSNs is causally related to the dyskinesias
(11–17). A very similar D1R sensitization occurs in drug abuse
(18,19), but enhanced D1R signaling in addiction induces an
increase in spine density in nucleus accumbens MSNs (20–25).
Thus, D1R sensitization might induce similar structural changes in
dyskinesias and drug abuse. Here we ask whether the dyskinesias
are related to changes in the dendritic arbor of striatal MSNs.
Moreover, because molecular sensitization to D1R stimulation
is associated with an enhanced metabolic response of striatum
to D1 agonists (15), we tested the hypothesis that striatal MSNs
are more excitable in dyskinetic mice. We used a mouse model
of parkinsonism induced by unilateral injection of 6-hydr-
oxydopamine (6-OHDA) in the adult striatum (16,26). The
restricted pattern of nigrostriatal degeneration affecting the
motor district of the striatum in this animal model allowed
us to correlate morphological and functional changes in MSN to
the degree of striatal denervation and to test whether the
dyskinesias are associated with any additional alteration of MSN
dendrites.BIOL PSYCHIATRY 2014;75:711–722
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This study was carried out in 3–4-month-old male C57BL6
wild-type (WT) and bacterial artiﬁcial chromosome (BAC)-trans-
genic mice (D1R-tomato or D2R–enhanced green ﬂuorescent
protein [eGFP]). Animals were housed and maintained following
the guidelines from European Union Council Directive (86/609/
European Economic Community). Mice received an intrastriatal
6-OHDA (Sigma-Aldrich, Madrid, Spain) injection (parkinsonian
group) or vehicle (sham group), as described previously (26). The
mice recovered for 2–3 weeks and then began saline or L-DOPA
treatment for 15 days (dyskinetic group). The treatment consisted
of a daily intraperitoneal injection of 10 mg/kg benserazide
hydrochloride (Sigma-Aldrich) followed 20 min later by an intra-
peritoneal injection of 25 mg/kg of L-DOPA (Sigma-Aldrich) or
two saline injections 20 min apart.
Behavior
Dyskinesias were studied in WT, D1R-tomato, and D2R-eGFP
mice three times/week, 30 min after treatment, as described
previously (26). We measured orofacial and limb dyskinesias as
well as axial dystonia individually with a 0–4 score scale for each
animal. After the last L-DOPA injection, total axial, limb, and
orofacial dyskinesia were measured every 20 min over a period of
180 min to see the dyskinetic proﬁle over time.
Immunohistochemistry
Anesthetized animals were transcardially perfused with 4%
paraformaldehyde (pH 7.4) 1 hour after the last L-DOPA injection.
Brains were postﬁxed for 24 hours, and coronal sections were
obtained on a vibratome (Leica, Madrid, Spain). The cutting
sequence was 200-, 30-, 30-, and 30-μm-thick sections throughout
the entire striatum. The thicker sections were used for Lucifer-Yellow
injections, whereas the 30-μm sections were used for tyrosine
hydroxylase (TH) and FosB immunostainings. Immunostaining was
performed in free-ﬂoating sections with standard avidin-biotin
protocols (27) with the following rabbit antisera: TH (1:1000;
Chemicon, Temecula, California); FosB (1:7,500; Santa Cruz Biotech-
nology, Santa Cruz, California); and Lucifer-Yellow (1:100,000) (28).
Morphology
We used 200-μm sections from D1R-tomato and D2R-eGFP
mice for morphological neuron reconstruction. The D1R- and
D2R-positive MSNs from BAC-transgenic mice were visualized
with the Cherry (for D1R-positive) or GFP (for D2R-positive
neurons) ﬂuorescence ﬁlters. To visualize D1R- or D2R-negative
MSNs, striatal slices were labeled with 4’,6-diamidino-2-phenyl-
indole (Sigma-Aldrich). The MSNs were injected individually with
Lucifer-Yellow (8% in .05% Tris-buffer, pH 7.4; Sigma-Aldrich) by
passing a hyperpolarizing current (10–20 nA). Then, sections were
processed for immunocytochemistry with the anti-Lucifer-Yellow
antibody (see preceding text). Neurolucida (MicroBrightField,
Williston, Vermont) was used to trace dendritic arbors of MSNs
three-dimensionally and to mark spines. Only neurons that were
completely ﬁlled were included for analysis. Filled neurons
located near the lesion needle track were discarded. Quantiﬁca-
tions were done by a researcher blind to the experimental
conditions.
Electrophysiology
The WT mice (3–4–month–old) were decapitated, and their
brains were removed and dropped into ice-cold Krebs-Ringer-
bicarbonate solution containing (in mmol/L): 119 sodium chloride,www.sobp.org/journal26.2 sodium bicarbonate, 2.5 potassium chloride, 1 potassium
dihydrogenorthophosphate, 1.3 magnesium sulphate, 2.5 calcium
chloride, and 11 glucose, gassed with 95% oxygen and 5% carbon
dioxide. Transverse corticostriatal slices (400-μm-thick) were cut
and stored for 1 hour at room temperature. Recordings were
performed in a submersion-type chamber continuously perfused
(1.8–2 ml/min) with standard Krebs-Ringer-bicarbonate solution
at 31–321C. Stock solutions of picrotoxin (5 mmol/L; Sigma-
Aldrich), SKF38393 hydrochloride (15 mmol/L; Sigma-Aldrich),
and SCH23390 hydrochloride (1 mmol/L; Tocris, London, United
Kingdom) were diluted to their ﬁnal concentrations in the
perfusion solution immediately before use. Intracellular record-
ings of dorsal striatal neurons were obtained with borosilicate
glass micropipettes (1.5 mm outer diameter) pulled on a Flaming/
Brown puller (P-87; Sutter Instrument, Novato, California) and
ﬁlled with 2 mol/L potassium chloride (50–80 MΩ), which were
connected to an Axoclamp-2B ampliﬁer (Axon Instruments, Foster
City, California) used in bridge mode. The MSNs were identiﬁed
by ﬁring patterns (29). Input resistance (Rin) was calculated from
the voltage defection produced by hyperpolarizing current pulses
(.1–.2 nA) of 100-msec duration. Action potentials were elicited by
200-msec-long rectangular .3–.8-nA depolarizing pulses.
Statistical Analysis
Data were expressed as mean  SEM unless stated otherwise.
Statistical differences (Systat-Software, San Jose, California; IBM
SPSS Statistics version 20, Madrid, Spain) were assessed by one-
or two-way analysis of variance followed by Bonferroni t test;
a value of p  .05 was considered statistically signiﬁcant. Compar-
isons between cumulative frequency distribution were done with
the Friedman test.Results
Induction of Dyskinesias in 6-OHDA-Lesioned Mice
To quantify L-DOPA-induced dyskinesias in parkinsonian WT,
D1R-tomato, or D2R-eGFP mice, we scored orofacial, limb, and
locomotive dyskinesia 30 min after L-DOPA or saline injection as
previously described (14,16,26). After L-DOPA, parkinsonian BAC-
transgenic mice developed marked dyskinetic movements affect-
ing the contralateral forelimb and orofacial structures, together
with trunk dystonia, similar to those observed in WT mice
(Figure 1A). These symptoms were not observed in the saline
group. In all three genotypes, dyskinesias were maximal
30–60 min after L-DOPA, as observed in the time response curve
performed on Day 14, and gradually declined to baseline levels
over 180 min (Figure 1B), consistent with previous results
(16,26,30).
Previous studies have shown that dyskinesias in parkinsonian
mice are related to increased phosphorylation of extracellular
signal-regulated kinase–1/2 and augmented expression of ΔFosB
and prodynorphin in the striatum [(26,31) reviewed in (19)]. We
now show that, as shown previously in WT (16,26), in the BAC-
transgenic mice, FosB induction only takes place in severely
denervated striatal areas where the density of remaining dop-
aminergic ﬁbers falls to 10% of control levels (referred to here
as the “totally denervated area”). Dyskinesias only appear when
portions of the dorsolateral striatum are almost completely
denervated, inducing substantial changes in FosB expression
(Figure 1C) in all types of mice. There were no signiﬁcant
differences in TH or FosB expression between the different
genotypes.
Figure 1. Dyskinesias and their molecular markers are
similar in hemiparkinsonian wild-type (WT) mice and in
dopamine receptor D1 (D1R)-tomato and D2R–enhanced
green ﬂuorescent protein (eGFP) bacterial artiﬁcial chro-
mosome transgenic mice. (A) Total dyskinesia (Dysk) score
(axial dystonia plus limb and orolingual Dysk) in WT (n ¼
10), D1R-tomato (n ¼ 8), and D2R-eGFP mice (n ¼ 7).
Measurements were taken 20 min after saline or L-DOPA
treatment. (B) Duration of dyskinetic effect on Day 14. The
total Dysk score was measured every 30 min for 180 min.
(C) Representative coronal striatal sections showing tyro-
sine hydroxylase (TH) (top) and FosB expression (bottom)
from sham, parkinsonian, and dyskinetic WT, D1R-tomato,
and D2R-eGFP mice. Note the correspondence between
severe TH ﬁber depletion and expression of FosB (*p 
.005; **p  .001 vs. saline, two-way analysis of variance).
Park, parkinsonian mice.
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Arborization
In ﬁxed striatal slices MSNs from WT, D1R-tomato, or D2R-eGFP
mice were injected with Lucifer-Yellow through a microelectrode
(Figure 2A–G). In D1R-tomato mice, we reconstructed D1R-
positive (red ﬂuorescence) and D1R-negative (no ﬂuorescence)Figure 2. Complete morphological reconstruction of striatal medium spiny neur
section of the striatum under low magniﬁcation. (B–D) Serial striatal sections sho
The black line shows the boundary of the totally denervated striatal area (10%
LY-injected MSNs before (E) and after (F, G) 3,3’-diaminobenzidine immunostain
one shown in G corresponds to a partially denervated area. Cx, cortex; Str, striMSNs. Similar reconstructions were done of D2R-positive (green-
ﬂuorescence) and D2R-negative (no ﬂuorescence) MSNs in D2R-
eGFP mice to test for possible compensatory mechanisms related
to construction of BAC-transgenic mice.
To determine the effects of 6-OHDA lesion on the dendritic tree,
MSNs were fully reconstructed from two areas: one with partialons (MSNs). (A) Lucifer-Yellow (LY) labeled MSNs in a 200-mm-width coronal
wing TH (B), LY (C), and FosB (D) immunostaining from a dyskinetic mouse.
residual TH ﬁbers). (E–G) High magniﬁcation microphotographs showing
ing. The MSNs shown in E and F are from a totally denervated area, and the
atum; V, ventricle; other abbreviations as in Figure 1.
www.sobp.org/journal
Figure 3. Cell body area of MSNs is not altered in
parkinsonian or dyskinetic mice. (A) Drawings of represen-
tative MSNs in sham, parkinsonian, and in dyskinetic mice
from WT, D1R-tomato, and D2R-eGFP mice. (B) Cell body
area of MSNs from sham, parkinsonian, and dyskinetic WT,
D1R-tomato, and D2R-eGFP mice. The WT mice group: n ¼
35 from 7 sham; n ¼ 45 from 7 parkinsonian; and n ¼ 57
from 12 dyskinetic mice. The D1R-tomato mice group: D1R-
positive, ﬂuorescence red, MSNs (n ¼ 28 from 4 sham, n ¼
27 from 5 parkinsonian, n ¼ 22 from 5 dyskinetic mice); and
D1R-negative, no ﬂuorescence, MSNs (n ¼ 16 from 3 sham,
n ¼ 29 from 5 parkinsonian, and n ¼ 36 from 6 dyskinetic
mice). The D2R-eGFP mice group: D2R-negative, no ﬂuor-
escence (n ¼ 20 from 4 sham, n ¼ 36 from 6 parkinsonian,
n ¼ 20 from 5 dyskinetic mice); and D2R-positive, green
ﬂuorescence MSNs (n ¼ 30 from 6 sham, n ¼ 27 from 5
parkinsonian, and n ¼ 35 from 8 dyskinetic mice). Cell body
area was similar in all experimental conditions. Lines
represent the mean, and each circle represents a single
neuron, in this and in the following ﬁgures. Abbreviations as
in Figures 1 and 2.
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and FosB expression in adjacent sections) (Figure 2B–D). Figure 2F
and G depicts representative MSNs from totally and partially
denervated striatal areas, respectively. Full three-dimensional mor-
phological reconstructions performed with NeuroLucida (Micro-
BrightField, Williston, Vermont) allowed us to assess the total
length and degree of dendritic arborization of MSNs (Figure 3A).
In WT mice there was no signiﬁcant difference in MSN cell body
area between parkinsonian (144  1.4), dyskinetic (143  .7), and
sham (142  1.4) mice in totally (Figure 3B) or partially denervated
striatal areas (Figure S1A in Supplement 1). Similarly, no changes
were observed in identiﬁed MSN from D1R-tomato or from D2R-
eGFP mice, under these experimental conditions (Figure 3B).
The total length of dendrites was also unchanged in WT
parkinsonian or dyskinetic mice (Figure 4A) and in identiﬁed MSN
from D1R-tomato or D2R-eGFP mice, regardless of their local-
ization in totally (Figure 4A) or partially denervated striatal areas
(Figure S1B in Supplement 1). These results were further sup-
ported by Sholl analysis of the dendritic arbors. Parkinsonian and
dyskinetic mice were not signiﬁcantly different in total dendritic
length (Figure 4B–E) or arborization (not shown) from sham mice.
This was true in WT, D1R-tomato, and D2R-eGFP mice and was
independent of MSN localization in totally or partially denervated
areas (not shown). Thus, the data show that neither denervation
nor chronic L-DOPA administration changed the total length or
arborization of MSN in the mouse striatum.www.sobp.org/journalSpine Pruning Affects Both D1R- and D2R-MSNs in Highly
Denervated Striatal Territories
There is a debate about whether spine loss in the striatum
preferentially affects the D2R-MSNs or equally affects D1R- and
D2R-expressing MSNs (8–10). To answer this question, we
assessed dendritic spines with two different BAC-transgenic
mouse lines, D1R-tomato and D2R-GFP, in comparison with WT
C57BL6 mice. We ﬁrst assessed sham mice and observed that the
number of dendritic spines in unidentiﬁed MSN from WT mice
(7.5  .2) is similar to that in identiﬁed MSNs from D1R-tomato or
D2R-eGFP mice (7.2  .3 and 8.2  .2, respectively) (Figure 5B).
Striatal 6-OHDA lesion caused a signiﬁcant decrease in spine
density in totally denervated areas of WT mice (Figure 5B), as
previously demonstrated (7). In D1R-tomato parkinsonian mice,
spine density decreased equally in D1R-positive (4.7  .2) and
-negative (4.6  .3) MSNs located within the totally denervated
areas (Figure 5B). Similarly, dopaminergic denervation decreased
spine density in both D2R-positive and -negative MSNs
(Figure 5B). Cumulative frequencies of spine number of D1R-
and D2R-positive MSNs indicate that 6-OHDA lesions reduce spine
density similarly in both types of neurons (Figure 5C). A detailed
study of spine density at increasing distances from the soma
showed that the effect of total denervation was homogeneous
along the dendritic arbor (Figures 6A–C). Thus, total nigrostriatal
denervation induces an almost 30% decrease in the number of
dendritic spines in both D1R- and D2R-MSNs (Figure 6B,C). This
Figure 4. Total dendritic length of MSNs is not altered in
parkinsonian or dyskinetic mice. (A) Total length of the
dendritic arbor of MSNs located in totally denervated areas
from WT, D1R-tomato, or D2R-eGFP mice in the different
experimental conditions. (B) Concentric circles (15 μm)
centered in the cell body of a reconstructed MSN,
illustrating the Sholl analysis of the dendritic arbor. (C–E)
Total dendritic length as a function of distance from the
soma in the different experimental groups: WT (C); D1R-
tomato (D); or D2R-eGFP (E) mice. The n is described in
Figure 3. Abbreviations as in Figures 1 and 2.
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denervated striatal areas with a TH-loss  90% there was no
change in spine density in unidentiﬁed MSNs from parkinsonian
WT mice or in identiﬁed neurons from parkinsonian D1R-tomato
or D2R-eGFP mice (Figure 7).
Chronic L-DOPA Selectivity Restores Spine Density in
Denervated D2R-MSNs
Studies in rodents treated with cocaine and psychostimulants
show that repeated stimulation of dopamine receptors increases
spine density in nucleus accumbens MSNs in correlation with
behavioral sensitization (20–25). Because sensitization mecha-
nisms underlie L-DOPA-induced dyskinesia, we checked whether
similar changes in spine density occur in our mice. Chronic
administration of L-DOPA at doses inducing dyskinesia signiﬁ-
cantly increased the number of spines on MSN from WT mice
(Figures 5B and 6A), although spine density remained signiﬁcantly
lower than in sham animals.
To see whether this increase occurs in one or both types of
MSN, similar experiments were carried out in BAC-transgenic mice.
In dyskinetic D1R-tomato mice, L-DOPA treatment did not change
the spine density of D1R-positive MSNs after denervation (4.4  .3
compared with 4.7  .2, in dyskinetic and parkinsonian mice,respectively) (Figure 5B). By contrast, the number of spines in D1R-
negative MSNs signiﬁcantly increases after L-DOPA treatment, from
4.6  .3 to 7.3  .4 (p  .005) (Figure 5B). Strikingly, after L-DOPA,
spine density in the D1R-negative MSNs reaches normal density
values observed in sham mice (8.2  .2). Our ﬁndings in D2R-eGFP
mice conﬁrmed these results (Figure 5B). As expected, spine density
was similar in D2R-negative and D1R-positive MSN (4.4  .3 and
4.4  .3, respectively), and the number of spines in D2R-positive
and D1R-negative MSN was similar to sham control mice (8.6  .3,
7.3  .3, and 8.0  .3, respectively). Cumulative frequencies of
spine number of D1R- and D2R-positive MSNs indicate that L-DOPA
increases spines in D2R-positive MSNs but not in D1R-positive
MSNs of dyskinetic mice (Figure 5C). These results indicate that
L-DOPA treatment induces reversal of denervation-induced spine
pruning, selectively in D2R-containing MSNs.
Sholl analysis conﬁrmed that spine density increases in D1R-
negative and D2R-positive MSNs from dyskinetic mice were
homogeneous along the dendritic arbor (45–165 mm)
(Figure 6B,C). Chronic L-DOPA administration had no effect on
the number of dendritic spines on MSNs in partially denervated
striatal areas in any of the genotypes examined (Figure 7). Thus,
unlike psychostimulants in intact brains, which increase MSN
spine density above normal levels, L-DOPA increases spinewww.sobp.org/journal
Figure 5. Chronic L-DOPA treatment selectively upregulates spine density in totally denervated D2R-MSNs. (A) Representative examples of confocal and
optic microscopic images of MSN dendrites of WT (top), D1R-tomato (central), and D2R-eGFP (bottom) mice under different experimental conditions. The
color of LY ﬂuorescence was altered to show D1R-positive MSNs from D1R-tomato mice in red and D2R-positive MSNs from D2R-eGFP mice in green.
(B) Average spine density along the MSN dendritic arbor (45–105 μm from soma) from WT, D1R-tomato, or D2R-eGFP mice in the different experimental
conditions in totally denervated areas. Spine density of MSNs decreased in all parkinsonian groups. The L-DOPA treatment selectively restored spine
number in D1R-negative and in D2R-positive MSNs from D1R-tomato and from D2R-eGFP dyskinetic mice, respectively. (C) Cumulative frequencies of
spine density of D1R-positive and D2R-positive MSNs of sham-lesioned, parkinsonian, and dyskinetic mice. Gray traces in the graphic represent MSNs from
sham mice to facilitate comparison between experimental groups. Inset bar graphs show the average  SEM of spine density to facilitate the comparison
between the direct and indirect striatal pathway projection neurons (the n is described in Figure 3; *p  .05 vs. sham; γ  .001 vs. D1R-positive; ♯p  .001
vs. D2R-negative, two-way ANOVA; Ψp  .05 Kruskal-Wallis test). Abbreviations as in Figures 1 and 2.
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Figure 6. Chronic L-DOPA treatment restores spine density along the dendritic arbor of D2R-MSNs located in dopamine depleted areas. (A–C) Spine
density as function of distance from the soma in WT (A), D1R-tomato (B), and D2R-eGFP (C) mice under the different experimental conditions. The
6-hydroxydopamine lesions (parkinsonian mice) decreased the spine density of MSNs along dendrites (45 mm from cell body in all three types of mice).
The L-DOPA treatment (dyskinetic mice) selectively restored spine number in D1R-negative (B) and in D2R-positive (C) MSNs from D1R-tomato and D2R-
eGFP, respectively. Gray traces in the graphic represent MSNs from sham mice to facilitate comparison between experimental groups. The n is described in
Figure 3 (*p  .05; **p  .001 vs. sham; γp  .05, and γγp  .001 vs. D1R-negative MSNs; ♯p  .05 and ♯♯p  .001 vs. D2R-negative MSNs, two-way analysis
of variance). Abbreviations as in Figures 1 and 2.
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spines are lost after denervation, restoring it to normal levels.
Enhanced Responsiveness to D1R Stimulation in Striatal
Neurons Contributing to Dyskinesia
Previous studies (32–34) have demonstrated changes in MSN
excitability in dopamine denervated striatum. Moreover, current
models propose that dyskinesia is related to hyperactivity of D1R-
MSNs (14,16,26,30,35,36). We performed experiments to establish
the functional consequence of dopamine depletion and L-DOPAtreatment on intrinsic electrical properties of MSNs in corticostriatal
slices from sham, parkinsonian, and dyskinetic mice. Many electro-
physiological properties of MSNs in denervated striatal regions were
not altered by nigrostriatal denervation or by L-DOPA treatment,
including resting membrane potential, Rin, and action potential
amplitude (32) (Table 1). With somatic current-clamp recordings, we
characterized the pattern of action potentials evoked by depolariz-
ing pulses applied through the recording pipette and found
that MSNs were signiﬁcantly more excitable in parkinsonian than
sham mice. Chronic L-DOPA almost completely restored normalwww.sobp.org/journal
Figure 7. Partial dopaminergic denervation is sufﬁcient to sustain normal spine density in MSNs. (A) Representative examples of confocal and
optic microscopic images of dendritic spines of MSNs located in partially denervated areas from WT D1R-tomato, and D2R-eGFP mice under the different
experimental conditions. The color of LY ﬂuorescence was altered to show positive MSNs from D1R-tomato mice in red and from D2R-eGFP mice in green.
(B) Average number of dendritic spines in MSNs (45–105 μm away from soma). (C–E) Spine Sholl analysis of MSN located in partially denervated areas of
WT (C), D1R-tomato (D), and D2R-eGFP (E) mice. The WT group: n = 66 from 7 sham; n = 38 from 7 parkinsonian; and n = 62 from 12 dyskinetic mice. The
D1R-tomato group: D1R-positive, ﬂuorescence red, MSNs (n = 33 from 4 sham, n = 17 from 5 parkinsonian, n = 23 from 5 dyskinetic mice); and D1R-
negative, no ﬂuorescence, MSNs (n = 17 from 3 sham, n = 23 from 5 parkinsonian, and n = 15 from 6 dyskinetic mice). The D2R-eGFP group: D2R-
negative, no ﬂuorescence (n = 24 from 4 sham, n = 17 from 6 parkinsonian, n = 12 from 5 dyskinetic mice); and D2R-positive, green ﬂuorescence MSNs
(n = 30 from 6 sham, n = 15 from 5 parkinsonian, and n = 32 from 8 dyskinetic mice). Abbreviations as in Figures 1 and 2.
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Table 1. Intrinsic Membrane Properties of MSNs
Action Potential
RMP (mV) Rin (mΩ) Amplitude (mV) Duration (msec) Firing Threshold (mV)
Sham Saline −88.19  .99 45.63  1.44 89.06  1.70 .75  .02 48.98  .74
L-DOPA −90.85  1.51 47.49  2.47 89.99  2.01 .81  .04 51.74  1.01
Lesion Park −88.95  1.46 47.94  2.58 89.84  1.40 .84  .02a 52.55  1.29a
Dysk −87.74  2.08 46.52  2.46 88.35  1.56 .82  .02 52.32  .84
Sham saline (n ¼ 19 from 14 mice); L-DOPA (n ¼ 13 from 9 mice); parkinsonian (Park) (n ¼ 14 from 7 mice); dyskinetic (Dysk) (n ¼ 20 from 9 mice).
MSNs, medium spiny neurons; Rin, input resistance; RMP, resting membrane potential.
ap  .05 parkinsonian vs. sham in saline treatment (one-way analysis of variance; Bonferroni post hoc).
L.M. Suárez et al. BIOL PSYCHIATRY 2014;75:711–722 719excitability (Figure 8). Increased excitability in denervated animals
coincided with a decrease in action potential threshold (Table 1).
The selective D1R agonist SKF38393 applied to the bath (3 or
10 mmol/L) had no effect on depolarization-induced action poten-
tial ﬁring in sham mice (Figure 9A,B) but increased evoked ﬁring in
parkinsonian mice. The effect was weak in vehicle-treated parkin-
sonian mice but was greatly enhanced in mice that had shown
L-DOPA-induced dyskinesia (p ¼ .02 in parkinsonian mice)
(Figure 9B). This increase was reversed by bath co-application of
SKF38393 plus a selective D1R antagonist, SCH23390 (10 mmol/L)
(Figure 9C). The D1R agonist-induced increase in ﬁring rate was not
associated with major changes in intrinsic properties of MSNs
(Table 2). Thus nigrostriatal denervation enhances MSN excitability,
whereas chronic L-DOPA enhances a positive modulatory effect of
the D1R on excitability.
Discussion
Here we show that 6-OHDA lesions in the striatum reduce spine
density in D1R-positive and D2R-positive MSN of D1R-tomato and
D2R-eGFP BAC-transgenic mice. This reduction was similar to that
observed in unidentiﬁed MSN in WT C57BL6 mice. We further show
that these changes are restricted to totally denervated striatal
areas. A major ﬁnding of the present study is that chronic L-DOPA,at doses inducing dyskinesia, reverses dendritic spine loss selec-
tively in striatal MSNs expressing the D2R. These MSNs are part of
the indirect, striatopallidal projection pathway. These results were
obtained in D1R-negative MSN from D1R-tomato mice and in D2R-
positive MSN from D2R-eGFP mice. L-DOPA does not affect spine
pruning in the D1R- MSNs, which form the direct striatonigral
pathway. Moreover, MSNs showed an enhanced ﬁring rate during
current injection in parkinsonian animals. Although chronic
L-DOPA reversed this hyperexcitability, it also enhanced a positive
modulatory effect of the D1R on evoked ﬁring. Thus, MSNs show
more marked responses to injected current during D1R stimulation
in dyskinetic than in parkinsonian mice.
We found that spine pruning only occurs in striatal regions with
severe striatal denervation. Regions with more than 10% of
dopaminergic ﬁbers spared showed no sign of dendritic pathology.
This is in general agreement with ﬁndings by Villalba et al. (10) in
l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP)–lesioned monkeys,
but Villalba et al. suggested a graded parallel pattern of dendritic
pathology and dopaminergic ﬁber loss, whereas our results
suggest a threshold of dopamine ﬁber depletion for dendritic
pathology. However, because a graded pattern would be difﬁcult
to detect in the small mouse striatum, the possibility remains that,
after a given threshold is surpassed, dendritic pathology is graded
according to extent of dopamine ﬁber loss.Figure 8. Enhanced excitability of MSNs in denervated
striatum. (A) Representative recording of discharge evoked
during current injection in MSNs of each experimental
group. Note the enhanced response in parkinsonian
compared with the sham saline condition. (B) Intensity
response curves of saline-treated mice. (C) Intensity
response curves of L-DOPA-treated mice. The sham saline
curve is represented in B and C to facilitate visual
comparisons. Inset graph shows the ﬁring rate of MSNs
from parkinsonian and dyskinetic mice to facilitate the
comparison (*p  .01; **p  .001 vs. sham, two-way
repeated measures ANOVA). Of note, L-DOPA signiﬁcantly
reduced excitability in parkinsonian mice (p  .01). Sham
mice (n = 19 neurons from 14 mice treated with saline;
n = 13 neurons from 9 mice treated with L-DOPA); parkin-
sonian mice (n = 14 neurons from 7 mice); and dyskinetic
mice (n = 20 neurons from 9 mice). Abbreviations as in
Figures 1 and 2.
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Figure 9. Enhanced responsiveness to D1 receptor stimulation in the
denervated striatum. (A) Representative traces of MSNs in the different
experimental groups, before (black) and during (blue) application of the
selective D1 agonist SKF38393 to the bath (10 mmol/L). (B) Percentage of
MSNs that ﬁre action potential in response to SKF38393 (3 or 10 mmol/L,
as indicated) application in sham mice treated with saline (n = 19 from 14
mice) or L-DOPA (n = 13 from 9 mice) and in parkinsonian (n = 14 from
7 mice) and dyskinetic mice (n = 20 from 9 mice). Signiﬁcant effects were
seen at SKF38393 (10 mmol/L) in dyskinetic mice (p  .05, Friedman test).
(C) Representative traces (right) showing evoked action potentials (400 pA
current pulse) of MSN from dyskinetic mice recorded under basal
conditions, during bath application of SKF38393 (10 mmol/L) alone (blue)
or with SCH23390 (10 mmol/L; red). The ﬁring rate as function of injected
current (left) in MSNs from dyskinetic mice (n = 6 from 3 mice). The ﬁring
rate increases during bath application of 10 mmol/L SKF38393 (blue
scatterplot) (*p  .05; **p  .001 vs. baseline, two-way analysis of
variance) and returns to basal values during the co-application with
SCH23390 (red plot). Abbreviations as in Figures 1 and 2.
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striatum preferentially affects the D2R-MSNs projecting to the
globus pallidus (indirect pathway) or equally affects D1R-MSNs
(direct pathway) and D2R-MSNs (8–10). Day et al. (8) reported that
spine loss is limited to D2R-MSNs in mouse models of parkinson-
ism. Then, in MPTP-lesioned monkeys, Scholz et al. (9) conﬁrmedwww.sobp.org/journalspine depletion in D2R-MSN but showed an augmented spine
density in D1R-MSNs. Finally, Villalba et al. (10) found a similar
depletion of spines in D1R-positive neurons and putative D2R-
expressing neurons in MPTP-lesioned monkeys. Our results show
that spine pruning affects both D1R- and D2R-MSNs in parkinso-
nian mice. Moreover, the spine decrease was found in two
different BAC-transgenic animal lines: D1R-tomato and D2R-eGFP
mice. We cannot explain the discrepancy between our results and
those of Day et al., although different models of parkinsonism
were used (reserpine vs. intrastriatal 6-OHDA injections) as well as
different techniques (ex vivo vs. postmortem neuronal ﬁlling) and
different-age mice (25-day vs. 3–4-month old).
One of the aims of the present study was to determine
whether dendritic pathology is modiﬁed by L-DOPA treatment.
This is important because the dendritic pathology observed in
patients could be a consequence of the natural history of the
disease, of treatment, or of an interaction between the two.
Although the available human studies included control subjects
without any known brain pathology, all PD patients in these
studies received L-DOPA chronically (4,5). Our results here dem-
onstrate that dopamine denervation-induced spine pruning is
reversed by L-DOPA treatment in D2R-MSNs but not in D1R-MSNs.
It has been suggested that spine pruning after dopamine denerva-
tion is induced by an increase in glutamatergic transmission
(8,37,38). It is possible that L-DOPA restores striatal glutamatergic
release to normal levels (39,40), producing a recovery of spines
in MSNs. The question then is: “Why does spine recovery occur
selectively in D2R-MSNs?” Although morphological studies
evidence a similar glutamatergic innervation to D1R- and to
D2R-MSNs (41), electrophysiological studies (38) showed that
D2R-MSNs have stronger cortical inputs and are more directly
affected by cortical activity than D1R-MSNs. Although speciﬁc
studies in dyskinetic animals are lacking, indirect evidence
suggests that L-DOPA treatment would inhibit the response of
D2R-MSNs to cortical input (42,43). Thus, L-DOPA treatment could
increase the number of spines in D2R-MSN in an attempt to
overcome the inhibition. By contrast, L-DOPA-induced dyskinesia
is associated with alterations in glutamate (AMPA and NMDA) and
dopamine (D1) receptor interaction and trafﬁcking within the
postsynaptic membrane (44–46). Moreover, D1R stimulation dur-
ing L-DOPA treatment could be expected to potentiate glutamate
effects on D1R-MSNs (43,47). Thus, it is possible that, although
glutamate release returns to normal levels after L-DOPA, post-
synaptic glutamatergic transmission remains altered in D1R-MSNs,
blocking the recovery of spines because of the aforementioned
abnormal dopamine–glutamate receptor interaction. These points
are in line with the opposing role of dopamine receptors on
glutamatergic transmission (D1R potentiate, whereas D2R inhibit
glutamate-mediated currents) and might relate to changes to
maintain, as far as possible, the cellular homeostasis.
Although spine re-growth in D2R-MSNs in dyskinetic mice
might respond to the restoration of glutamate levels and D2R-
mediated inhibition in the striatum, a remaining issue is whether
these new spines form physiological synapses. We think this is
unlikely, because spine re-growth is not accompanied by physio-
logical dopaminergic re-innervation. If these new spines do form
synapses, with which cell types do they synapse? One possibility is
that they make contact with glutamatergic afferents (39), forming
abnormal synapses in the absence of tonic dopamine modulation
and setting the grounds for L-DOPA-induced dyskinesia.
Previous studies showed that MSN membrane excitability is
enhanced in denervated striatum (32,34). Here, we extend these
results by showing that, in parkinsonian mice, the action potential
Table 2. Intrinsic Membrane Properties of MSNs Measured After SKF38393
Action Potential
RMP (mV) Rin (mΩ) Amplitude (mV) Duration (msec) Firing Threshold (mV)
Sham Saline −87.41  1.70 42.14  1.97 87.12  2.10 .75  .01 49.29  .89
L-DOPA −89.75  1.52 44.90  2.41 92.19  2.19 .85  .007 52.17  1.12
Lesion Park −87.23  2.01 45.71  2.06 89.05  2.11 .89  .003 50.17  1.40
Dysk −85.75  2.48 45.22  2.11 89.34  2.17 .84  .04 53.75  1.01
Intrinsic membrane properties of MSNs measured after SKF38393, 10 μmol/L bath application (7 min). Sham saline (n ¼ 19 from 14 mice); L-DOPA (n ¼
13 from 9 mice); Park (n ¼ 14 from 7 mice); Dysk (n ¼ 20 from 9 mice). Abbreviations as in Table 1.
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injection is increased. One candidate to mediate lesion-induced
changes in excitability is A-type potassium current, which has
well-known effects on action potential ﬁring and whose inactiva-
tion is regulated by dopamine in MSNs (48). In fact, Azdad et al.
(34) found that A-type potassium current inactivation is faster in
parkinsonian than in control rats, resulting in an augmented
excitability similar to what we found here in parkinsonian mice.
It has been proposed that the high basal excitability of MSN in
nontreated dopamine-depleted animals represents a homeostatic
mechanism that maintains neuronal ﬁring despite the loss of
excitatory synapses (34). A remaining question is whether this
hyperexcitability at single cell level is associated with anomalous
neuronal synchronization and changes in network dynamic status
after dopamine depletion (49).
L-DOPA treatment restores evoked ﬁring in response to current
injection to nearly normal levels, but our data also show that the
L-DOPA-induced dyskinesia is accompanied by a marked sensiti-
zation, enhancing the effects of D1R stimulation in MSNs without
changes in the ﬁring threshold. Our results show a slight although
not signiﬁcant depolarization of MSNs in dyskinetic mice during
SKF38393 bath application (Tables 1 and 2), which could explain
the increase in D1R-mediated responses. Previous work has shown
dual effects of D1R on MSN excitability through the modulation of
sodium-, potassium-, and calcium-voltage-dependent currents,
which are available at different membrane potentials observed
in vivo (50,51). Thus, D1R modulation of any of these currents
might be altered in dyskinetic mice. Because no D1R enhancing
effect on excitability is seen in slices from sham mice treated with
L-DOPA (32,52), it must be considered as an abnormal response to
nigrostriatal denervation, which is further enhanced in dyskinesias.
This striatal hyperexcitability to D1R stimulation might mediate the
widespread metabolic and electrophysiological changes observed
in dyskinetic animals and patients (15,53–56). We speculate that, in
dyskinetic mice, the ﬁring response of MSNs to injected current
during application of a D1R agonist reﬂects more closely what
happens in patients taking L-DOPA than the baseline slice
condition where dopamine is low in parkinsonian mice.
Overall, our ﬁndings reveal two new correlates of dyskinesia:
L-DOPA restores spine density selectively in D2R-MSNs and induces
an abnormal D1R-mediated enhancement of MSN ﬁring responses
to membrane depolarization. These changes might contribute to the
postulated functional imbalance favoring the direct over the indirect
pathway, which is predicted by basal ganglia models to underlie
dyskinesia. New experiments are necessary to determine whether
the new spines induced in D2R-MSNs by L-DOPA form functional
synapses.
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